Portage Biotech (Portage Biotech) EV-to-EBIT : 0.00 (As of Apr. 29, 2024)

View and export this data going back to . Start your Free Trial

What is Portage Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Portage Biotech's Enterprise Value is $-0.31 Mil. Portage Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-169.34 Mil. Therefore, Portage Biotech's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Portage Biotech's EV-to-EBIT or its related term are showing as below:

During the past 13 years, the highest EV-to-EBIT of Portage Biotech was 0.58. The lowest was -20.32. And the median was -2.47.

PRTG's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.4
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Portage Biotech's Enterprise Value for the quarter that ended in Dec. 2023 was $30.26 Mil. Portage Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-169.34 Mil. Portage Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -559.60%.

Portage Biotech EV-to-EBIT Historical Data

The historical data trend for Portage Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portage Biotech EV-to-EBIT Chart

Portage Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-EBIT

Get a 7-Day Free Trial

-43.86

-25.12

-26.04

-7.35

-0.35

Portage Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-4.49	-0.35	-0.44	-0.27	-0.18

Competitive Comparison of Portage Biotech's EV-to-EBIT

For the Biotechnology subindustry, Portage Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Portage Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portage Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Portage Biotech's EV-to-EBIT falls into.

Portage Biotech EV-to-EBIT Calculation

Portage Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-0.314	/	-169.341
	=	0.00

Portage Biotech's current Enterprise Value is $-0.31 Mil.
Portage Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-169.34 Mil.

Portage Biotech (NAS:PRTG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Portage Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-169.341	/	30.261324
	=	-559.60 %

Portage Biotech's Enterprise Value for the quarter that ended in Dec. 2023 was $30.26 Mil.
Portage Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-169.34 Mil.

Portage Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Portage Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Portage Biotech (Portage Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110

Website

https://www.portagebiotech.com

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.